ストックスクリーナーアプリを入手
2.71
0.37%
-0.01
アフターアワーズ：
2.70
-0.010
-0.37%
Poseida Therapeutics Inc (PSTX) 最新ニュース
Poseida Therapeutics to Present at Two Upcoming Investor Conferences - Marketscreener.com
Poseida Therapeutics, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2024 - Marketscreener.com
Poseida Therapeutics (NASDAQ:PSTX) Earns Buy Rating from HC Wainwright - Defense World
Poseida Therapeutics Provides Update on Cell Therapy Research ProgramsOn November 14, 2024, Poseida Therapeutics, Inc. issued a press release providing an update on its cell therapy research and development programs. Members of the management - Defense World
Poseida Therapeutics offers preclinical highlights of CAR T pipeline - BioWorld Online
Where Poseida Therapeutics Stands With Analysts - Benzinga
Poseida Therapeutics (NASDAQ:PSTX) Receives "Buy" Rating from HC Wainwright - MarketBeat
Poseida Therapeutics Hosts Cell Therapy R&D Day Highlighting Its Innovative Clinical and Preclinical Pipeline - PR Newswire
Poseida Therapeutics, Inc. (PSTX) Is Up 24.70% in One Week: What You Should Know - MSN
Poseida Therapeutics, Inc. (PSTX) Q3 Earnings and Revenues Beat Estimates - MSN
Poseida Therapeutics’ (PSTX) Buy Rating Reaffirmed at HC Wainwright - Defense World
Poseida Therapeutics (PSTX) to Present at Major Stifel, Piper Sandler Healthcare Conferences | PSTX Stock News - StockTitan
HC Wainwright Reiterates Buy Rating for Poseida Therapeutics (NASDAQ:PSTX) - MarketBeat
Poseida Therapeutics Third Quarter 2024 Earnings: Beats Expectations - Yahoo Finance
Gene Therapy Market to Grow by USD 6.74 Billion from 2024-2028, as Rise in Special Drug Designations Drives Demand with AI-Powered Market EvolutionTechnavio - The Malaysian Reserve
Poseida Therapeutics Reports Strong Q3 2024 Progress - TipRanks
Poseida Therapeutics Provides Updates and Financial Results for the Third Quarter of 2024 - PR Newswire
Poseida Therapeutics to present cancer cell therapy data at SITC, ASH - Investing.com India
Poseida Therapeutics to Present Clinical and Preclinical Data on Investigational Allogeneic CAR-T Cell Therapies at SITC 2024 and ASH 2024 - Lelezard
Poseida Therapeutics to Present Clinical and Preclinical Data on Investigational Allogeneic CAR-T Cell Therapies at SITC 2024 and ASH 2024 – Company AnnouncementFT.com - Financial Times
Poseida Therapeutics (STU:2RZ) Degree of Operating Leverage : -9.17 (As of Jun. 2024) - GuruFocus.com
Poseida Therapeutics' (PSTX) Buy Rating Reaffirmed at HC Wainwright - MarketBeat
Poseida Therapeutics Receives Regenerative Medicine Advanced The - GuruFocus.com
Poseida Therapeutics to Present New Preclinical Data Supporting Non-Viral Gene Editing with P-KLKB1-101 for the Treatment of Hereditary Angioedema - PR Newswire
VRTX: 3 Pharma Stocks to Watch as Gene Therapy Gains Momentum - StockNews.com
Investors Don't See Light At End Of Poseida Therapeutics, Inc.'s (NASDAQ:PSTX) Tunnel And Push Stock Down 30% - Simply Wall St
Third development candidate nominated under Poseida and Roche’s allogeneic CAR T collaboration - BioWorld Online
Poseida shares hold as analyst reiterates buy rating on MM study - Investing.com
Poseida Nominates New Development Candidate Under Its Collaboration With Roche - Contract Pharma
Poseida Therapeutics (NASDAQ:PSTX) Rating Reiterated by HC Wainwright - MarketBeat
Poseida advances with new CAR-T therapy candidate - Investing.com
Poseida Therapeutics Announces Nomination of New CAR-T Development Candidate Under Collaboration with Roche - StockTitan
Quarterly Metrics: Quick and Current Ratios for Poseida Therapeutics Inc (PSTX) - The Dwinnex
Marshall Wace LLP Buys Shares of 10,538 Poseida Therapeutics, Inc. (NASDAQ:PSTX) - Defense World
MaxCyte Appoints Cynthia Collins to its Board of Directors - The Manila Times
The Anatomy Of Astellas And Poseida's CAR-T Deal - In Vivo
PSTXPoseida Therapeutics, Inc. Latest Stock News & Market Updates - StockTitan
Poseida Therapeutics’ Allogeneic CAR-T P-BCMA-ALLO1 Demonstrates 91% ORR in Enhanced Lymphodepletion Arm of R/R MM Study - CGTLive™
Ratio Examination: Poseida Therapeutics Inc (PSTX)’s Price-to-Cash and Price-to-Free Cash Flow - The Dwinnex
Poseida Therapeutics Inc (PSTX) deserves closer scrutiny - US Post News
Poseida Therapeutics Named to Newsweek's List of the Top 200 America's Most Loved Workplaces for 2024 - IT News Online
Poseida Therapeutics (STU:2RZ) Long-Term Capital Lease Obli - GuruFocus.com
Poseida Therapeutics (STU:2RZ) Net Change in Cash : €-18.49 Mil (TTM As of Jun. 2024) - GuruFocus.com
Anchoring Your Portfolio: Is PSTX Stock a Safe Harbor? - The InvestChronicle
Poseida Therapeutics, Inc. (NASDAQ:PSTX) Shares Acquired by Renaissance Technologies LLC - MarketBeat
Roche-Poseida Lead Allogeneic CAR-T Advances after Showing Promise in Multiple Myeloma - Genetic Engineering & Biotechnology News
A new trading data show Poseida Therapeutics Inc (PSTX) is showing positive returns. - SETE News
Poseida stock supported by strong data from P-BCMA-ALLO-1, says BTIG - Investing.com South Africa
Piper Sandler maintains Overweight rating on Poseida Therapeutics shares - Investing.com
Poseida Therapeutics' SWOT analysis: gene therapy stock shows promise amid challenges - Investing.com India
Poseida Therapeutics reveals promising trial results for myeloma treatment - Investing.com
Poseida: Interim P-BCMA-ALLO1 Data Bodes Well For Phase 1B Advancement - Seeking Alpha
0.93%
3.55%
大文字化:
|
ボリューム (24 時間):